EP0845979A1 - Cosmetic method for treating and preventing the signs of skin ageing - Google Patents
Cosmetic method for treating and preventing the signs of skin ageingInfo
- Publication number
- EP0845979A1 EP0845979A1 EP97922001A EP97922001A EP0845979A1 EP 0845979 A1 EP0845979 A1 EP 0845979A1 EP 97922001 A EP97922001 A EP 97922001A EP 97922001 A EP97922001 A EP 97922001A EP 0845979 A1 EP0845979 A1 EP 0845979A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- retinoid
- composition
- skin
- mentioned
- retinoids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 35
- 230000032683 aging Effects 0.000 title claims abstract description 13
- 239000002537 cosmetic Substances 0.000 title claims abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 89
- 150000004492 retinoid derivatives Chemical class 0.000 claims abstract description 21
- 239000002085 irritant Substances 0.000 claims abstract description 8
- 230000037303 wrinkles Effects 0.000 claims abstract description 6
- 238000011200 topical administration Methods 0.000 claims abstract 5
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 25
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 16
- 229960003471 retinol Drugs 0.000 claims description 15
- 235000020944 retinol Nutrition 0.000 claims description 15
- 239000011607 retinol Substances 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 229960001727 tretinoin Drugs 0.000 claims description 6
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 5
- 239000007764 o/w emulsion Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 229930002330 retinoic acid Natural products 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 230000000475 sunscreen effect Effects 0.000 claims description 3
- 239000000516 sunscreening agent Substances 0.000 claims description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 239000000058 anti acne agent Substances 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 230000001153 anti-wrinkle effect Effects 0.000 claims description 2
- 229940124340 antiacne agent Drugs 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 235000020945 retinal Nutrition 0.000 claims description 2
- 150000003726 retinal derivatives Chemical class 0.000 claims description 2
- -1 retinoid salts Chemical class 0.000 claims description 2
- 235000002639 sodium chloride Nutrition 0.000 claims description 2
- 206010040954 Skin wrinkling Diseases 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 1
- 239000013066 combination product Substances 0.000 abstract 1
- 229940127555 combination product Drugs 0.000 abstract 1
- 125000002678 retinoid group Chemical group 0.000 abstract 1
- 238000009472 formulation Methods 0.000 description 44
- 206010040914 Skin reaction Diseases 0.000 description 13
- 230000035483 skin reaction Effects 0.000 description 13
- 231100000430 skin reaction Toxicity 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000007794 irritation Effects 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QELSKZZBTMNZEB-UHFFFAOYSA-N p-hydroxybenzoic acid propyl ester Natural products CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 6
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 5
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 5
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 5
- 229940101267 panthenol Drugs 0.000 description 5
- 235000020957 pantothenol Nutrition 0.000 description 5
- 239000011619 pantothenol Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 4
- 229960001631 carbomer Drugs 0.000 description 4
- 229960000541 cetyl alcohol Drugs 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 4
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 4
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 4
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 4
- 229960002216 methylparaben Drugs 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N n-hexadecyl alcohol Natural products CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 4
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 4
- 229960003415 propylparaben Drugs 0.000 description 4
- 239000004264 Petrolatum Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 229940066842 petrolatum Drugs 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- 244000067456 Chrysanthemum coronarium Species 0.000 description 2
- 235000007871 Chrysanthemum coronarium Nutrition 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantion Natural products NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229940081733 cetearyl alcohol Drugs 0.000 description 2
- 229940074979 cetyl palmitate Drugs 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 239000011928 denatured alcohol Substances 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N n-octadecyl alcohol Natural products CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 229960001679 octinoxate Drugs 0.000 description 2
- 229940100460 peg-100 stearate Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical class C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-MKOSUFFBSA-N 9-cis-retinol Chemical compound OC\C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-MKOSUFFBSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- SYESMXTWOAQFET-YCNIQYBTSA-N all-trans-3,4-didehydroretinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=CCC1(C)C SYESMXTWOAQFET-YCNIQYBTSA-N 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- NZZIMKJIVMHWJC-UHFFFAOYSA-N dibenzoylmethane Chemical compound C=1C=CC=CC=1C(=O)CC(=O)C1=CC=CC=C1 NZZIMKJIVMHWJC-UHFFFAOYSA-N 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960004881 homosalate Drugs 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- SHGAZHPCJJPHSC-XFYACQKRSA-N isotretinoin Chemical compound OC(=O)/C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-XFYACQKRSA-N 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 206010024217 lentigo Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N n-butyl para-hydroxybenzoate Natural products CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 229960001173 oxybenzone Drugs 0.000 description 1
- RARSHUDCJQSEFJ-UHFFFAOYSA-N p-Hydroxypropiophenone Chemical compound CCC(=O)C1=CC=C(O)C=C1 RARSHUDCJQSEFJ-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229940105297 polyglyceryl-2 diisostearate Drugs 0.000 description 1
- 229940101631 quaternium-18 hectorite Drugs 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-O triethanolammonium Chemical compound OCC[NH+](CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-O 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- the present invention relates to the treatment of the skin using compositions containing retmoids, in order to combat skin ageing and the formation of wrinkles More particularly, the invention relates to a method for the cosmetic treatment of the skin, m particular the face, the neck or the hands, with retinoid compositions, which is less irritant than the known methods and allows the individual to use higher and more effective doses during the treatment, and at an earlier stage than previously
- patent US-5,401,517 suggests using a lower dose of retmoids for several days and then increasing the dose of retmoids in the composition on the following days, when the sk has become accustomed to the compounds.
- this method has drawbacks since it requires a change in the application regime to use a different formulation containing a higher dose of retinoid. This places the onus on the user to remember to change product and to buy an additional product before the first one has been used up.
- compositions containing low doses of retmoids are used during the day but allow the individual to apply formulations containing a higher, more effective dose in the evening before going to bed. All of each tube of product will be used during the treatment, thus avoiding any loss of product and excessive costs.
- the application procedure will remain similar from the initial day of the treatment, which will thereby encourage the individual to acquire suitable habits and to maintain these habits from the first day of use.
- the individual applies high doses of retinoids from the start of the treatment and thus obtains the benefits of high doses immediately.
- one of the subjects of the inven ⁇ tion is to provide a method for treating the skin by applying an effective amount of retinoid onto the skin during the day, in order to combat the ageing process.
- Another of the subjects of the invention is to provide a method for treating the skin with retinoids and for attenuating the irritation produced by retinoids.
- Another of the subjects of the invention is to provide a method for treating the skin which allows a high dose of retinoids to be applied from the first day of use .
- Another subject of the invention is to provide a method for treating the skin which allows the individual to use the retinoid-based product on a daily basis from the start of the treatment.
- the invention relates to a method for treating the skin according to the following procedure : a) application of a composition containing a weak dose of retinoids, comprising a compound of retinoid type which is effective for combating skin ageing, at a sub-irritant dose, once a day; and b) application of a composition containing a higher dose of retinoids approximately 10 to 16 hours, advantageously 12 hours, after the first dose.
- composition formulated specifi- cally for a part of the face for example the eyes, may be applied once or twice a day at a low, sub-irritant dose.
- the formulations serving as vehicle for each of the applications of the product in the method according to the invention may be identical or may be different, depending upon the particular requirements of the regime and of the user.
- a base or a lighter formulation may be used during the day whilst a richer emulsion of firmer consistency may be used at night for greater skin comfort while the individual is resting.
- the aim pursued in developing the invention is to allow the individual using retinoid-based compositions to become more tolerant to retinoids more quickly. Often, individuals react by developing red ⁇ ness, itchiness, stinging, a burning sensation and desquamation when retinoids are applied. However, by using retinoids in an application procedure according to the present invention, the individuals may tolerate the application of retinoids at an effective dose more quickly then if an amount which produces the irritation had to be applied immediately on a daily basis.
- retinoids should be understood to include retinoic acid or tretinoin, retinol, retinaldehydes and salts and esters thereof.
- Typical salts are alkali metal, ammonium and C 2 -C 30 ammonium salts.
- the sodium, potassium, triethanolammonium and ammonium salts are particularly preferred. Combinations of all the above compounds may be present in the compositions.
- retinol and retinoic acid should be understood to include hydrogenated and non-hydrogenated isomers such as 9-cis-retinol, didehydroretinol, 13-cis- retinoic acid, 13-trans-retinoic acid and didehydro- retinoic acid.
- Other retinoids which are effective in treating skin ageing, wrinkles and other anomalies are present in US patents Nos. 4,603,146, 4,887,805 and 4,888,342, the contents of which are incorporated herein by way of reference . They may be present in the compositions used according to the invention at concen ⁇ trations from about 0.0001 % to about 5 %.
- they will be present in amounts of between 0.0001 % and about 0.3 %. Even more preferably, they must be present in amounts of between about 0.01 % and about 0.075 %. Even more preferably, they are present in amounts of between about 0.015 % and about 0.04 %.
- the concentrations will be determined by those skilled in the art according to the nature of the retinoids specifically present in the composition. They will also be adapted as a function of the excipients and of the ability of the formulation to release active retinoid molecules which can be used by the skin. A large variety of pharmaceutically and/or cosmetologically acceptable supports may be used for the present invention.
- the amounts of vehicles may be from about 1 to 99.9 % and preferably from about 80 to 98 %, advantageously between about 95 and about 99.950 % of the composition by weight.
- compositions used in the products according to the invention as vehicles or bases may be in the form of emulsions, such as oil-in-water or water-in-oil emulsions. They may also be in the form of liposomal emulsions or any other emulsion known to those skilled in the art, which are physically and chemically stable.
- the compositions which may be used in the method according to the invention comprise water-in-oil emulsions as described in EP 91 9137059 which is incorporated herein by way of reference.
- Oil-in-water formulations which may be used in the method according to the invention are presented in WO/US 95/11750 which is incorporated herein by way of reference .
- Liposomal compositions wnich may be used as vehicles for the retinoid compositions in the method according to the invention are described in WO/US 96/04557 which is incorporated herein by way of reference.
- compositions may also be formulated in gel or lotion form with cosmetologically acceptable excipients known to those skilled in the art.
- compositions according to the invention may also be included in the compositions according to the invention.
- ingredients may include, in parti- cular, sunscreens and screening agents, tanning agents, antiacne agents, in particular salicylic acid, antiinflammatories (in particular panthenol, Gingko biloba, glycyrrhetinic acid, etc.) , depigmenting agents, hydrating agents, plant extracts and other anti-wrinkle agents.
- the sunscreens comprise, in particular, 4-aminobenzoic acid and derivatives thereof, dibenzoyl- methane, camphor derivatives, homosalate, oxybenzone, cinnamic esters, 3-imidazol-4-ylacrylic acid and benz- imidazole derivatives such as 2-phenylbenzimidazole- 5-sulphonic acid and its sodium and TEA salts.
- the first application of the day should be made in the morning, after cleansing the skin, on waking up.
- the first application should contain a sub-irritant dose of retinoids, for example from about 0.0001 % to about 0.04 % and preferably less than 0.04 %, advantageously from 0.01 % to 0.02 %.
- a particularly suitable concentration is 0.015 % by weight.
- the first application may preferably be made in an oil-in-water emulsion which is relatively light and easy to apply and to wear.
- the second application should preferably be made in the evening, just before going to bed and approximately 10 to 16 hours after the first applica ⁇ tion.
- the second application should contain a relatively large amount of retinoids, which will allow the administration of a larger amount of retinoids onto the skin.
- This higher-concentration formulation will be more effective as a remedy for skin anomalies, since it contains a higher dose of active principles.
- This second application may be made in an oil-in-water emulsion. However, it may also be placed in a water-in- oil emulsion. Water-in-oil emulsions have a tendency to be slightly more nourishing and "greasy" than oil-in- water compositions. However, such formulations may be well tolerated at night and provide the skin with complementary moisturization.
- the retinoid content in the second application should preferably be from about 0.04 % to 0.3 %, although it may be higher if the patient is capable of tolerating this dosage.
- compositions specially formulated for particular areas of the upper part of the body such as the neck and around the eyes or the mouth, may be used in lower retinoid doses along with other formulations in order to provide additional assistance to these areas without causing any further irritation.
- the examples which follow are intended to illustrate the present invention without limiting its scope in any way.
- EXAMPLE 1 A composition containing retinol, having the formulation A and containing 0.015 % by weight of retinol, is applied daily to the face and the neck in the morning after cleansing the appropriate areas. In the evening, the neck and the face are again cleansed and a retinol formulation, having the composition B and containing 0.075 % by weight of retinol, is applied to the same area. The irritation symptoms are expected to be less than if a formulation containing about 0.04 % retinol was applied twice a day.
- the tolerance results are compared after treat ⁇ ment for 15 days and 1 month in 2 groups of users, according to two different administration procedures.
- the 1st group applies formulation A in the morning and formulation B in the evening as indicated above.
- a second group applies formulation C in the morning and formulation D in the evening under the same conditions.
- the tolerance is better in the 1st group, where less than 4 % of the individuals stop the application after 15 days.
- formulation A in the morning thus entails virtually no additional irritation but allows the skin to be prepared to receive the dose present in formulation B and to adjust the total daily dose administered.
- formulation E in the morning may thus be combined with that of a stronger-dosed formulation, such as formulation B, in the evening, onto the entire face.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9607110 | 1996-06-07 | ||
FR9607110A FR2749511B1 (fr) | 1996-06-07 | 1996-06-07 | Methode cosmetique de traitement et de prevention des signes du vieillissement de la peau |
PCT/IB1997/000642 WO1997046221A1 (en) | 1996-06-07 | 1997-06-05 | Cosmetic method for treating and preventing the signs of skin ageing |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0845979A1 true EP0845979A1 (en) | 1998-06-10 |
Family
ID=9492845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97922001A Withdrawn EP0845979A1 (en) | 1996-06-07 | 1997-06-05 | Cosmetic method for treating and preventing the signs of skin ageing |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP0845979A1 (cs) |
JP (1) | JPH11510824A (cs) |
KR (1) | KR19990036233A (cs) |
CN (1) | CN1198092A (cs) |
AU (1) | AU2786197A (cs) |
BR (1) | BR9702284A (cs) |
CA (1) | CA2228750A1 (cs) |
CZ (1) | CZ31798A3 (cs) |
EA (1) | EA199800194A1 (cs) |
FR (1) | FR2749511B1 (cs) |
HU (1) | HUP9802916A3 (cs) |
PL (1) | PL324929A1 (cs) |
WO (1) | WO1997046221A1 (cs) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6017549A (en) * | 1997-09-30 | 2000-01-25 | E-L Management Corp. | Non-irritating cosmetic and pharmaceutical compositions |
KR100404868B1 (ko) * | 2000-03-28 | 2003-11-15 | 김삼 | 안정한 레티놀 팔미테이트 및 그를 함유하는 화장료 조성물 |
FR2817475B1 (fr) * | 2000-12-04 | 2005-06-17 | Rocher Yves Biolog Vegetale | Utilisation d'une association proteases-source de retinol pour s'opposer au vieillissement cutane |
WO2003053327A2 (en) * | 2001-12-20 | 2003-07-03 | Johnson & Johnson Consumer France S.A.S. | Compositions containing a retinoid and malt extract |
US20050019356A1 (en) * | 2003-07-25 | 2005-01-27 | The Procter & Gamble Company | Regulation of mammalian keratinous tissue using N-acyl amino acid compositions |
CA2747939C (en) * | 2008-12-22 | 2016-11-08 | Thierry Oddos | A composition comprising a retinoid and method of treating skin conditions |
JP2013056867A (ja) * | 2011-09-09 | 2013-03-28 | Pias Arise Kk | 概日リズム調整用キット及び概日リズムの調整方法 |
US10639252B2 (en) * | 2011-09-23 | 2020-05-05 | Allergan, Inc. | Compositions for skin exfoliation and use thereof |
FR3006191B1 (fr) * | 2013-06-03 | 2016-04-29 | Pierre Fabre Dermo-Cosmetique | Compositions cosmetiques ou dermatologiques associant du retinaldehyde et de l'oleamide de glycylglycine, et leurs utilisations en cosmetique ou dermatologie |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA945068A (en) * | 1967-10-25 | 1974-04-09 | Albert M. Kligman | Composition and method of treating acne |
US5401517A (en) * | 1993-11-15 | 1995-03-28 | Elizabeth Arden Company, Division Of Conopco, Inc. | Cosmetic method for treatment of skin |
-
1996
- 1996-06-07 FR FR9607110A patent/FR2749511B1/fr not_active Expired - Fee Related
-
1997
- 1997-06-05 AU AU27861/97A patent/AU2786197A/en not_active Abandoned
- 1997-06-05 CN CN97190973A patent/CN1198092A/zh active Pending
- 1997-06-05 EA EA199800194A patent/EA199800194A1/ru unknown
- 1997-06-05 CA CA002228750A patent/CA2228750A1/en not_active Abandoned
- 1997-06-05 KR KR1019980700901A patent/KR19990036233A/ko not_active Application Discontinuation
- 1997-06-05 HU HU9802916A patent/HUP9802916A3/hu unknown
- 1997-06-05 WO PCT/IB1997/000642 patent/WO1997046221A1/en not_active Application Discontinuation
- 1997-06-05 EP EP97922001A patent/EP0845979A1/en not_active Withdrawn
- 1997-06-05 JP JP10500379A patent/JPH11510824A/ja active Pending
- 1997-06-05 CZ CZ98317A patent/CZ31798A3/cs unknown
- 1997-06-05 PL PL97324929A patent/PL324929A1/xx unknown
- 1997-06-05 BR BR9702284-5A patent/BR9702284A/pt not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO9746221A1 * |
Also Published As
Publication number | Publication date |
---|---|
FR2749511B1 (fr) | 1998-08-28 |
AU2786197A (en) | 1998-01-05 |
WO1997046221A1 (en) | 1997-12-11 |
CA2228750A1 (en) | 1997-12-11 |
BR9702284A (pt) | 1999-12-28 |
EA199800194A1 (ru) | 1998-08-27 |
CZ31798A3 (cs) | 1998-06-17 |
FR2749511A1 (fr) | 1997-12-12 |
HUP9802916A2 (hu) | 1999-03-29 |
JPH11510824A (ja) | 1999-09-21 |
CN1198092A (zh) | 1998-11-04 |
KR19990036233A (ko) | 1999-05-25 |
PL324929A1 (en) | 1998-06-22 |
HUP9802916A3 (en) | 1999-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU639063B2 (en) | Skin care compositions | |
EP0989846B1 (en) | Non-irritating cosmetic and pharmaceutical compositions | |
US6955816B2 (en) | Anti-aging skin care composition and uses thereof | |
JPH1087476A (ja) | ヒドロキシ酸またはレチノイドを含有する組成物中の刺激防止剤としてのルリヂサ種子油 | |
WO1996014085A1 (fr) | Preparation dermoprotectrice d'usage externe | |
EP1216696A2 (en) | Method for reducing the appearance of dark circles under the eyes | |
EP0687467A2 (de) | Wirkstoffkombinationen mit einem Gehalt and Glyceylalkylethern und kosmetische und dermatologische Zubereitungen, solche Wirkstoffkombinationen enthaltend | |
US7655255B2 (en) | Topical composition for transdermal administration | |
JP2937446B2 (ja) | 白髪防止黒化剤 | |
US20220183951A1 (en) | Skin treatment methods and compositions with retinoid and delivery systems thereof | |
US20190151214A1 (en) | Methods and compositions for treatment of skin | |
EP0845979A1 (en) | Cosmetic method for treating and preventing the signs of skin ageing | |
EP1192939A2 (en) | Methods for reduction of inflammation and erythema | |
EP1219288A2 (en) | Treatment for skin | |
EP1192940A1 (en) | Compositions and methods for promoting clear skin using an alkanolamine | |
US20050019354A1 (en) | Topical benfotiamine treatments | |
JPH11302133A (ja) | 頭皮頭髪用化粧料 | |
JPH10273424A (ja) | 頭髪用化粧料 | |
JPH10273422A (ja) | 頭髪用化粧料 | |
AU2006201889A1 (en) | Treatment for skin | |
AU2004242563A1 (en) | Method for promoting clear skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: RO PAYMENT 980302 |
|
17P | Request for examination filed |
Effective date: 19980525 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Withdrawal date: 20000221 |